Yes. In the case of tuberculosis—to pick up the most worrying example among the three diseases—we face very significant global health security threats with multi-drug resistant TB. Multi-drug resistant TB represents a third of the antimicrobial resistance-related deaths in the world. One-third are related to TB. This is, indeed, a very important issue.
To give some sense of the scale, in 2017 there were 558,000 new cases with resistance. We see that as a threat for people living with TB, obviously, but also a global threat because it could easily spread.
We are investing in research in that area, together with Unitaid. We don't do research ourselves, but of course we work with partners. We are working very closely with Unitaid to come up with new solutions—new drugs—to improve the treatment for multi-drug resistant TB. The treatments so far are very long, not very successful and very painful for the patients, so a lot more definitely needs to be done in that area.